262 related articles for article (PubMed ID: 26407819)
1. Sensitivity of neuroblastoma to the novel kinase inhibitor cabozantinib is mediated by ERK inhibition.
Zhang L; Scorsone K; Woodfield SE; Zage PE
Cancer Chemother Pharmacol; 2015 Nov; 76(5):977-87. PubMed ID: 26407819
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer.
Bentzien F; Zuzow M; Heald N; Gibson A; Shi Y; Goon L; Yu P; Engst S; Zhang W; Huang D; Zhao L; Vysotskaia V; Chu F; Bautista R; Cancilla B; Lamb P; Joly AH; Yakes FM
Thyroid; 2013 Dec; 23(12):1569-77. PubMed ID: 23705946
[TBL] [Abstract][Full Text] [Related]
3. The novel kinase inhibitor EMD1214063 is effective against neuroblastoma.
Scorsone K; Zhang L; Woodfield SE; Hicks J; Zage PE
Invest New Drugs; 2014 Oct; 32(5):815-24. PubMed ID: 24832869
[TBL] [Abstract][Full Text] [Related]
4. Dual inhibition using cabozantinib overcomes HGF/MET signaling mediated resistance to pan-VEGFR inhibition in orthotopic and metastatic neuroblastoma tumors.
Daudigeos-Dubus E; Le Dret L; Bawa O; Opolon P; Vievard A; Villa I; Bosq J; Vassal G; Geoerger B
Int J Oncol; 2017 Jan; 50(1):203-211. PubMed ID: 27922668
[TBL] [Abstract][Full Text] [Related]
5. TrkB inhibition by GNF-4256 slows growth and enhances chemotherapeutic efficacy in neuroblastoma xenografts.
Croucher JL; Iyer R; Li N; Molteni V; Loren J; Gordon WP; Tuntland T; Liu B; Brodeur GM
Cancer Chemother Pharmacol; 2015 Jan; 75(1):131-41. PubMed ID: 25394774
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma.
Daniel RA; Rozanska AL; Thomas HD; Mulligan EA; Drew Y; Castelbuono DJ; Hostomsky Z; Plummer ER; Boddy AV; Tweddle DA; Curtin NJ; Clifford SC
Clin Cancer Res; 2009 Feb; 15(4):1241-9. PubMed ID: 19174487
[TBL] [Abstract][Full Text] [Related]
7. Regorafenib is effective against neuroblastoma in vitro and in vivo and inhibits the RAS/MAPK, PI3K/Akt/mTOR and Fos/Jun pathways.
Subramonian D; Phanhthilath N; Rinehardt H; Flynn S; Huo Y; Zhang J; Messer K; Mo Q; Huang S; Lesperance J; Zage PE
Br J Cancer; 2020 Aug; 123(4):568-579. PubMed ID: 32457362
[TBL] [Abstract][Full Text] [Related]
8. Iodide- and glucose-handling gene expression regulated by sorafenib or cabozantinib in papillary thyroid cancer.
Ruan M; Liu M; Dong Q; Chen L
J Clin Endocrinol Metab; 2015 May; 100(5):1771-9. PubMed ID: 25768669
[TBL] [Abstract][Full Text] [Related]
9. Preclinical evaluation of dasatinib alone and in combination with cabozantinib for the treatment of diffuse intrinsic pontine glioma.
Truffaux N; Philippe C; Paulsson J; Andreiuolo F; Guerrini-Rousseau L; Cornilleau G; Le Dret L; Richon C; Lacroix L; Puget S; Geoerger B; Vassal G; Östman A; Grill J
Neuro Oncol; 2015 Jul; 17(7):953-64. PubMed ID: 25534822
[TBL] [Abstract][Full Text] [Related]
10. Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer.
Varkaris A; Corn PG; Parikh NU; Efstathiou E; Song JH; Lee YC; Aparicio A; Hoang AG; Gaur S; Thorpe L; Maity SN; Bar Eli M; Czerniak BA; Shao Y; Alauddin M; Lin SH; Logothetis CJ; Gallick GE
Clin Cancer Res; 2016 Jan; 22(1):107-21. PubMed ID: 26272062
[TBL] [Abstract][Full Text] [Related]
11. Cabozantinib and dastinib exert anti-tumor activity in alveolar soft part sarcoma.
Mukaihara K; Tanabe Y; Kubota D; Akaike K; Hayashi T; Mogushi K; Hosoya M; Sato S; Kobayashi E; Okubo T; Kim Y; Kohsaka S; Saito T; Kaneko K; Suehara Y
PLoS One; 2017; 12(9):e0185321. PubMed ID: 28945796
[TBL] [Abstract][Full Text] [Related]
12. Binimetinib inhibits MEK and is effective against neuroblastoma tumor cells with low NF1 expression.
Woodfield SE; Zhang L; Scorsone KA; Liu Y; Zage PE
BMC Cancer; 2016 Mar; 16():172. PubMed ID: 26925841
[TBL] [Abstract][Full Text] [Related]
13. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.
Yakes FM; Chen J; Tan J; Yamaguchi K; Shi Y; Yu P; Qian F; Chu F; Bentzien F; Cancilla B; Orf J; You A; Laird AD; Engst S; Lee L; Lesch J; Chou YC; Joly AH
Mol Cancer Ther; 2011 Dec; 10(12):2298-308. PubMed ID: 21926191
[TBL] [Abstract][Full Text] [Related]
14. Cabozantinib: a MET, RET, and VEGFR2 tyrosine kinase inhibitor.
Grüllich C
Recent Results Cancer Res; 2014; 201():207-14. PubMed ID: 24756794
[TBL] [Abstract][Full Text] [Related]
15. Improved therapy for neuroblastoma using a combination approach: superior efficacy with vismodegib and topotecan.
Chaturvedi NK; McGuire TR; Coulter DW; Shukla A; McIntyre EM; Sharp JG; Joshi SS
Oncotarget; 2016 Mar; 7(12):15215-29. PubMed ID: 26934655
[TBL] [Abstract][Full Text] [Related]
16. Small molecule inhibitor agerafenib effectively suppresses neuroblastoma tumor growth in mouse models via inhibiting ERK MAPK signaling.
Li H; Yu Y; Zhao Y; Wu D; Yu X; Lu J; Chen Z; Zhang H; Hu Y; Zhai Y; Su J; Aheman A; De Las Casas A; Jin J; Xu X; Shi Z; Woodfield SE; Vasudevan SA; Agarwal S; Yan Y; Yang J; Foster JH
Cancer Lett; 2019 Aug; 457():129-141. PubMed ID: 31100410
[TBL] [Abstract][Full Text] [Related]
17. Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo.
Momota H; Nerio E; Holland EC
Cancer Res; 2005 Aug; 65(16):7429-35. PubMed ID: 16103096
[TBL] [Abstract][Full Text] [Related]
18. Targeted inhibition of MEK1 by cobimetinib leads to differentiation and apoptosis in neuroblastoma cells.
Singh A; Ruan Y; Tippett T; Narendran A
J Exp Clin Cancer Res; 2015 Sep; 34(1):104. PubMed ID: 26384788
[TBL] [Abstract][Full Text] [Related]
19. Cabozantinib (XL184) Inhibits Growth and Invasion of Preclinical TNBC Models.
Sameni M; Tovar EA; Essenburg CJ; Chalasani A; Linklater ES; Borgman A; Cherba DM; Anbalagan A; Winn ME; Graveel CR; Sloane BF
Clin Cancer Res; 2016 Feb; 22(4):923-34. PubMed ID: 26432786
[TBL] [Abstract][Full Text] [Related]
20. Cabozantinib for the treatment of progressive metastatic medullary thyroid cancer.
Krajewska J; Olczyk T; Jarzab B
Expert Rev Clin Pharmacol; 2016; 9(1):69-79. PubMed ID: 26536165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
